VALIDATION AND UPDATING OF MODELS WITH BIOMARKERS

Slides:



Advertisements
Similar presentations
PERSONALIZED MEDICINE: Planning for the Future You, Your Biomarkers and Your Rights.
Advertisements

New concepts and guidelines in the management of LDL-c and CV Risk: Need for early intervention Prof. Ulf Landmesser University Hospital Zürich Switzerland.
The Relationship Between Repeat Infections and Behavioral Risk Factors and Clinician Counseling: Findings from a Philadelphia STD Clinic M. Eberhart 1,
Big Data and Predictive Analytics in Health Care Presented by: Mehadi Sayed President and CEO, Clinisys EMR Inc.
Assessing Disease Frequency
Prediction Models in Medicine Clinical Decision Support The Road Ahead Chapter 10.
Decision Theoretic Analysis of Improving Epidemic Detection Izadi, M. Buckeridge, D. AMIA 2007,Symposium Proceedings 2007.
Model and Variable Selections for Personalized Medicine Lu Tian (Northwestern University) Hajime Uno (Kitasato University) Tianxi Cai, Els Goetghebeur,
How do we know whether a marker or model is any good? A discussion of some simple decision analytic methods Carrie Bennette on behalf of Andrew Vickers.
A Risk Prediction Model for Recurrent Events in Chronic Coronary Heart Disease: The Heart and Soul Study Ivy Ku, Eric Vittinghoff, Kirsten Bibbins-Domingo,
Validation of predictive regression models Ewout W. Steyerberg, PhD Clinical epidemiologist Frank E. Harrell, PhD Biostatistician.
Coronary Calcium Scoring for Risk Stratification and Guidelines Matthew Budoff, MD, FACC, FAHA Professor of Medicine Director, Cardiac CT Harbor-UCLA Medical.
C-REACTIVE PROTEIN, FIBRINOGEN, AND CARDIOVASCULAR DISEASE PREDICTION By Patrick Whitledge PA-S2 South University Physician Assistant Program.
1 Comparing Zero Coronary Artery Calcium With Other Negative Risk Factors for Coronary Heart Disease A Novel Methodology: Risk-Adjusted Negative Likelihood.
Global impact of ischemic heart disease World Heart Federation, 2011.
Criteria for Assessment of Performance of Cancer Risk Prediction Models: Overview Ruth Pfeiffer Cancer Risk Prediction Workshop, May 21, 2004 Division.
Validation of Mayo Clinic Risk Adjustment Model for In-Hospital Mortality following Percutaneous Coronary Interventions using the National Cardiovascular.
© Copyright 2009 by the American Association for Clinical Chemistry Plasma Myeloperoxidase Predicts Incident Cardiovascular Risks in Stable Patients Undergoing.
Evidence-Based Practice A Stepwise Approach Bruce D. Friedman, PhD, ACSW, CSWM University of Texas – Pan American Social Work Department
Surrogate Endpoints and Correlative Outcomes Hem/Onc Journal Club January 9, 2009.
Evidence Based Practice
Division of Population Health Sciences Royal College of Surgeons in Ireland Coláiste Ríoga na Máinleá in Éirinn Indices of Performances of CPRs Nicola.
Patients’ preferences for preventive osteoporosis drug treatment EW de Bekker-Grob ML Essink-Bot WJ Meerding HAP Pols BW Koes EW Steyerberg Dept. Public.
Estimation of overweight-attributable deaths Katherine M. Flegal, Ph.D. Centers for Disease Control and Prevention National Center for Health Statistics.
BACKGROUND Cost-effectiveness of Psychotherapy for Cluster C Personality Disorders and the Value of Information and Implementation Djøra I. Soeteman 1,2,
EDRN Approaches to Biomarker Validation DMCC Statisticians Fred Hutchinson Cancer Research Center Margaret Pepe Ziding Feng, Mark Thornquist, Yingye Zheng,
How do we know whether a marker or model is any good? A discussion of some simple decision analytic methods Carrie Bennette (on behalf of Andrew Vickers)
Finding Relevant Evidence
LITERATURE REVIEW: THE WAY TO GET IDEA AND SUPPORT YOUR OPINION Ching-Chih Lee.
The Problem with Individual Risk Beverly Rockhill, Ph.D. Department of Epidemiology University of North Carolina, Chapel Hill.
Cost-effectiveness of Screening Tests Mark Hlatky, MD Stanford University.
Evaluating Risk Adjustment Models Andy Bindman MD Department of Medicine, Epidemiology and Biostatistics.
Prediction research Introduction and examples A. Cecile J.W. Janssens, PhD Professor of Translational Epidemiology.
Eating Disorder Prevention Programs: A Meta-Analytic Review Eric Stice and Heather Shaw Presented by Lisa Hoekzema Radford University.
Research Design Evidence Based Medicine Concepts and Glossary.
Relationship between performance measures: From statistical evaluations to decision-analysis Ewout Steyerberg Dept of Public Health, Erasmus MC, Rotterdam,
Prognostic modelling: General modelling strategy issues Ewout Steyerberg Professor of Medical Decision Making Dept of Public Health, Erasmus MC, Rotterdam,
Net Reclassification Risk: a graph to clarify the potential prognostic utility of new markers Ewout Steyerberg Professor of Medical Decision Making Dept.
Potential usefulness of a framework of 7 steps for prediction models Ewout Steyerberg Professor of Medical Decision Making Dept of Public Health, Erasmus.
Estimating Absolute Risk Reductions Associated with Interventions in Patients with Type 2 Diabetes Jim Mold, M.D., M.P.H. Brian Firestone, MS2.
Assessing the additional value of diagnostic markers: a comparison of traditional and novel measures Ewout W. Steyerberg Professor of Medical Decision.
PRAGMATIC Study Designs: Elderly Cancer Trials
 Adaptive Enrichment Designs for Confirmatory Clinical Trials Specifying the Intended Use Population and Estimating the Treatment Effect Richard Simon,
Prognostic Value of B-Type Natriuretic Peptides in Patients With Stable Coronary Artery Disease: The PEACE Trial Torbjørn Omland, MD, PHD, MPH, Marc S.
Measuring prognosis Patients want to know likely outcome
Evidence-based Medicine
Association between GDP and old-age mortality in seven European countries, A life-course perspective F.Janssen, A.E.Kunst, J.P.Mackenbach Department.
A high intra-patient variability in tacrolimus exposure is associated with poor long-term outcome of kidney transplantation Teun van Gelder Depts. of Pharmacy.
THE NURSING PROCESS A systematic problem-solving approach used to identify, prevent and treat actual or potential health problems and promote wellness.
Journal of Nuclear Cardiology | Official Journal of the American Society of Nuclear Cardiology Prediction of 14-year cardiovascular outcomes by dobutamine.
S117: Acute Setting Predictive Analytics Sharon E. Davis, MS
AMIA Joint Summits 2017 San Francisco
How to publish a world class paper?
From: Validation of a Risk Stratification Index and Risk Quantification Index for Predicting Patient Outcomes:In-hospital Mortality, 30-day Mortality,
HS4160 Critical Scientific Analysis
Figure 2 The US Centers for Disease Control and
Regulatory perspective
for the RODAM Consortium
National Society of Genetic Counselors: Position Statements
Comments on design and sequence of biomarker studies
Christine W. Duarte, PhD, Adam W. Black, Kimberly Murray, Amy E
Justification treatment cost
No Financial Disclosure or Conflict of Interest
Contributions to Cardiovascular Disease Prediction in the Women’s Health Study* Nancy R. Cook, et al. Circulation 2007;115:
Performance of Framingham cardiovascular disease (CVD) predictions in the Rotterdam Study taking into account competing risks and disentangling CVD into.
Regression and Clinical prediction models
YingXing Wu, MD, Gary L. Grunkemeier, PhD, Albert Starr, MD 
Building PHN Scientists
Prevalence and determinants of seborrhoeic dermatitis in a middle aged and elderly population: the Rotterdam Study M.G.H. Sanders, MD1, L.M. Pardo, MD,
Professor of Clinical Biostatistics and Medical Decision Making Nov-19 Why Most Statistical Predictions Cannot Reliably Support Decision-Making:
Presentation transcript:

VALIDATION AND UPDATING OF MODELS WITH BIOMARKERS Ewout W. Steyerberg, PhD Center for Medical Decision Making Dept of Public Health Erasmus MC, Rotterdam, the Netherlands E.Steyerberg@ErasmusMC.nl Utrecht, March 25, 2009

Erasmus MC – University Medical Center Rotterdam

Research

Contents Praise for Prof. Paul Ridker Prediction models for better decision making Validation and updating Extension with biomarker(s)

Search Google Scholar …

Prediction models for better decision making Identify low and high patients of cardiovascular disease better targeting of preventive interventions Predictions are probabilities No certainty Validation commonly includes calibration and discrimination Systematically too high / too low predictions Poorer performance than hoped for Better predictions with stronger predictors Much interest in biomarkers

Case study 1: validity of Framingham risk models Updating of regression coefficients: refitting Updating to average outcome: re-calibration

Validity of Framingham predictions (JAMA 2001)

Tab 1

Tab 3: Refit

Tab 5: Performance Improvement in c e.g. 0.67  0.70; native Americans even larger gains  ‘substantial improvement by using locally updated coefficients’ Recalibration important for better calibration

Case study 2: updating with a biomarker (Circulation 2008) Refitting of Framingham model Extension with CRP Many statistics to quantify improvement

Case study 3: updating with a set of biomarkers Refitting of Framingham model Extension with 4 biomarkers

Another example: NEJM 2008

Results: focus on c statistic

Elderly: mean 71 yrs

All markers add significantly, but NT-Pro-BNP is the winner

Substantial improvement in c statistics

.. and substantial NRI

Conclusions Model validation is followed by model updating and model extension Recalibration is a minimum Often new coefficients required Biomarkers need to be strong and beyond discovery phase Incremental contribution to traditional risk factors Be sceptical about new genetic signatures Quantification of model improvement challenging Patterns in C stat and net reclassification index (NRI) coincide No improvement in c  no improvement in NRI Improvement in decisions should be quantified by decision-analytic measures, weighing costs of wrong decisions, e.g. ‘Net Benefit’

Read more .. PubMed Paper with attendents of Kattan symposium “Accuracy of prediction models” Books

26